News | October 31, 2025
NATCO launches Everolimus tablets, 1 mg
Everolimus is an mTOR inhibitor immunosuppressant indicated for the prophylaxis of organ rejection in adult patients in kidney and liver transplantation
Everolimus is an mTOR inhibitor immunosuppressant indicated for the prophylaxis of organ rejection in adult patients in kidney and liver transplantation
Cobenfy generated $43 million in third-quarter sales, up from $35 million in the second quarter
ADX-248, which replaces ADX-743, is being developed for the treatment of metabolic inflammation, including obesity and hypertriglyceridemia
Vitiligo, affecting over 90 per cent of patients in its non-segmental form, is characterized by symmetrical white patches on both sides of the body
The FW500 is designed to meet the evolving needs of mid-sized diagnostic laboratories
New Phase III data on gefurulimab highlight potential as a self-administered treatment option; real-world evidence reinforces clinical benefits of Ultomiris and Soliris
AI-powered cardiometabolic wellness platform for India’s workforce
Test delivers results in just 18 minutes, enabling faster laboratory workflows and patient management during outbreaks
Subscribe To Our Newsletter & Stay Updated
